Staphylococcus aureus Mortality: U.S. Data & Context

CDC estimates ~19,000 U.S. deaths annually are attributable to Staphylococcus aureus infections (invasive MRSA + MSSA). This is likely an underestimate due to:

  • Attribution difficulty (comorbidities, polymicrobial infections)
  • Outpatient/non-invasive cases not captured
  • Surveillance gaps (not all states report uniformly)
  • Post-discharge mortality not fully tracked

Key Epidemiology

  • MRSA: ~80,000 invasive infections/year; ~11,000 deaths. Community-associated (CA-MRSA) now > healthcare-associated (HA-MRSA).
  • MSSA: More common; similar mortality per case.
  • High-risk groups: >65 yrs, hemodialysis, ICU, surgery, indwelling devices, immunosuppression, PWID.
  • Infection types: Bacteremia, endocarditis, osteoarticular, pneumonia, SSTI (skin/soft tissue).

Prevention & Control

  • Hand hygiene, contact precautions, chlorhexidine bathing (ICU).
  • Decolonization (intranasal mupirocin + CHG wash) pre-op, ICU, recurrent SSTI.
  • Antimicrobial stewardship (reduce selection pressure).
  • Vaccine candidates in trials (none licensed).
  • Surveillance: NHSN, EIP/ABCs.

Clinical Pearl

Any S. aureus bacteremia requires echocardiography (TTE → TEE if negative/high risk) for endocarditis, source control (remove lines, drain abscess), and 2–6 weeks IV antibiotics (β-lactam for MSSA; vancomycin/daptomycin/ceftaroline for MRSA).

Public Health - Related Articles